List of Tables
Table 1. Global Hyperuricemia Micromolecular Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Hyperuricemia Micromolecular Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Hyperuricemia Micromolecular Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Hyperuricemia Micromolecular Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Hyperuricemia Micromolecular Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Hyperuricemia Micromolecular Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Hyperuricemia Micromolecular Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Hyperuricemia Micromolecular Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hyperuricemia Micromolecular Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Hyperuricemia Micromolecular Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hyperuricemia Micromolecular Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Hyperuricemia Micromolecular Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Hyperuricemia Micromolecular Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Hyperuricemia Micromolecular Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Hyperuricemia Micromolecular Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Hyperuricemia Micromolecular Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Casper Pharma LLC Company Information
Table 71. Casper Pharma LLC Description and Business Overview
Table 72. Casper Pharma LLC Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Casper Pharma LLC Hyperuricemia Micromolecular Drugs Product
Table 74. Casper Pharma LLC Recent Developments/Updates
Table 75. GSK PLC Company Information
Table 76. GSK PLC Description and Business Overview
Table 77. GSK PLC Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. GSK PLC Hyperuricemia Micromolecular Drugs Product
Table 79. GSK PLC Recent Developments/Updates
Table 80. ASKA Pharmaceutical Holdings Co., Ltd Company Information
Table 81. ASKA Pharmaceutical Holdings Co., Ltd Description and Business Overview
Table 82. ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. ASKA Pharmaceutical Holdings Co., Ltd Hyperuricemia Micromolecular Drugs Product
Table 84. ASKA Pharmaceutical Holdings Co., Ltd Recent Developments/Updates
Table 85. Pfizer Inc. Company Information
Table 86. Pfizer Inc. Description and Business Overview
Table 87. Pfizer Inc. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Inc. Hyperuricemia Micromolecular Drugs Product
Table 89. Pfizer Inc. Recent Developments/Updates
Table 90. Takeda Pharmaceutical Co., Ltd Company Information
Table 91. Takeda Pharmaceutical Co., Ltd Description and Business Overview
Table 92. Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Takeda Pharmaceutical Co., Ltd Hyperuricemia Micromolecular Drugs Product
Table 94. Takeda Pharmaceutical Co., Ltd Recent Developments/Updates
Table 95. Viatris, Inc. Company Information
Table 96. Viatris, Inc. Description and Business Overview
Table 97. Viatris, Inc. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Viatris, Inc. Hyperuricemia Micromolecular Drugs Product
Table 99. Viatris, Inc. Recent Developments/Updates
Table 100. Menarini International Operations Company Information
Table 101. Menarini International Operations Description and Business Overview
Table 102. Menarini International Operations Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Menarini International Operations Hyperuricemia Micromolecular Drugs Product
Table 104. Menarini International Operations Recent Developments/Updates
Table 105. Suzuken Co., Ltd. Company Information
Table 106. Suzuken Co., Ltd. Description and Business Overview
Table 107. Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Suzuken Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 109. Suzuken Co., Ltd. Recent Developments/Updates
Table 110. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Company Information
Table 111. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Description and Business Overview
Table 112. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 114. Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 115. Eisai Co., Ltd. Company Information
Table 116. Eisai Co., Ltd. Description and Business Overview
Table 117. Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eisai Co., Ltd. Hyperuricemia Micromolecular Drugs Product
Table 119. Eisai Co., Ltd. Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Hyperuricemia Micromolecular Drugs Distributors List
Table 123. Hyperuricemia Micromolecular Drugs Customers List
Table 124. Hyperuricemia Micromolecular Drugs Market Trends
Table 125. Hyperuricemia Micromolecular Drugs Market Drivers
Table 126. Hyperuricemia Micromolecular Drugs Market Challenges
Table 127. Hyperuricemia Micromolecular Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Hyperuricemia Micromolecular Drugs
Figure 2. Global Hyperuricemia Micromolecular Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Hyperuricemia Micromolecular Drugs Market Share by Type: 2025 & 2032
Figure 4. 25-100 mg Product Picture
Figure 5. 100-300 mg Product Picture
Figure 6. Global Hyperuricemia Micromolecular Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Hyperuricemia Micromolecular Drugs Market Share by Application: 2025 & 2032
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Global Hyperuricemia Micromolecular Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Hyperuricemia Micromolecular Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Hyperuricemia Micromolecular Drugs Sales (K Units), 2021–2032
Figure 14. Global Hyperuricemia Micromolecular Drugs Average Price (US$/Unit), 2021–2032
Figure 15. Hyperuricemia Micromolecular Drugs Report Years Considered
Figure 16. Hyperuricemia Micromolecular Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Hyperuricemia Micromolecular Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Hyperuricemia Micromolecular Drugs Players: Market Share by Revenue in Hyperuricemia Micromolecular Drugs in 2025
Figure 19. Hyperuricemia Micromolecular Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Hyperuricemia Micromolecular Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Hyperuricemia Micromolecular Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Hyperuricemia Micromolecular Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Hyperuricemia Micromolecular Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Hyperuricemia Micromolecular Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Hyperuricemia Micromolecular Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Hyperuricemia Micromolecular Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Hyperuricemia Micromolecular Drugs by Type (2021–2032)
Figure 54. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Hyperuricemia Micromolecular Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Hyperuricemia Micromolecular Drugs by Application (2021–2032)
Figure 57. Global Hyperuricemia Micromolecular Drugs Price (US$/Unit) by Application (2021–2032)
Figure 58. Hyperuricemia Micromolecular Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
